A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis

Pauline T. Lukey, Stephen A. Harrison, Shuying Yang, Yim Man, Beverley F. Holman, Alaleh Rashidnasab, Gabrielle Azzopardi, Michael Grayer, Juliet K. Simpson, Philippe Bareille, Lyn Paul, Hannah V. Woodcock, Richard Toshner, Peter Saunders, Philip L. Molyneaux, Kris Thielemans, Frederick J. Wilson, Paul F. Mercer, Rachel C. Chambers, Ashley M. Groves, William A. Fahy, Richard P. Marshall, Toby M. Maher

Source: Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018
Journal Issue: March
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Pauline T. Lukey, Stephen A. Harrison, Shuying Yang, Yim Man, Beverley F. Holman, Alaleh Rashidnasab, Gabrielle Azzopardi, Michael Grayer, Juliet K. Simpson, Philippe Bareille, Lyn Paul, Hannah V. Woodcock, Richard Toshner, Peter Saunders, Philip L. Molyneaux, Kris Thielemans, Frederick J. Wilson, Paul F. Mercer, Rachel C. Chambers, Ashley M. Groves, William A. Fahy, Richard P. Marshall, Toby M. Maher. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: